News
HIV, CVS Health and Gilead Sciences
Digest more
The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...
Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...
Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...
Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...
Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.
Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback